Trypanocidal activity of nitroaromatic prodrugs: Current treatments and future perspectives

Current Topics in Medicinal Chemistry

Volumn 11, Issue 16, 2011, Pages 2072-2084

  Wilkinson, Shane R ^a   Bot, Christopher ^a   Kelly, John M ^b   Hall, Belinda S ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Aziridinyl nitrobenzamide; Benznidazole; Neglected diseases; Nifurtimox; Nitrobenzylphosphoramide mustard; Trypanosomal infections; Type I nitroreductase

Indexed keywords

ANTITRYPANOSOMAL AGENT; AROMATIC NITRO COMPOUND; AZIRIDINYL NITROBENZAMIDE DERIVATIVE; BENZNIDAZOLE; EFLORNITHINE; FEXINIDAZOLE; FURAZOLIDONE; HETEROCYCLIC COMPOUND; MELARSOPROL; METRONIDAZOLE; NIFURATEL; NIFUROXAZIDE; NIFURTIMOX; NIFURTOINOL; NIFURZIDE; NIMORAZOLE; NITROBENZYLPHOSPHORAMIDE MUSTARD DERIVATIVE; NITROFURAL; NITROFURANTOIN; NITROREDUCTASE; ORNIDAZOLE; PENTAMIDINE; PRODRUG; RADICAL; SATRANIDAZOLE; SECNIDAZOLE; SUPEROXIDE; SURAMIN; TINIDAZOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AFRICAN TRYPANOSOMIASIS; AGRANULOCYTOSIS; ALBUMINURIA; AMEBIASIS; ANEMIA; ANTIPROTOZOAL ACTIVITY; ARTICLE; ATAXIA; BACTERIAL INFECTION; BALANCE DISORDER; BRAIN DISEASE; BURN; CARCINOGENICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHAGAS DISEASE; CLINICAL TRIAL (TOPIC); CONFORMATIONAL TRANSITION; CONVULSION; DERMATITIS; DIARRHEA; DISORIENTATION; DRUG EFFICACY; DRUG FATALITY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME MECHANISM; EOSINOPHILIA; GASTROINTESTINAL INFECTION; GASTROINTESTINAL TOXICITY; GENOTOXICITY; GIARDIASIS; GINGIVITIS; HEMATURIA; HERXHEIMER REACTION; HUMAN; HYPERSENSITIVITY REACTION; HYPOGLYCEMIA; IMPOTENCE; INJECTION SITE PAIN; INSOMNIA; IRRITABILITY; LEUKOPENIA; MEMORY DISORDER; MUSCLE WEAKNESS; MUTAGENICITY; NAUSEA; NONHUMAN; NYSTAGMUS; PEPTIC ULCER; PERIODONTITIS; PERIPHERAL NEUROPATHY; PHLEBITIS; POLYNEUROPATHY; PSYCHOSIS; PURPURIC RASH; REACTIVE ARSENICAL ENCEPHALOPATHY; REDUCTION; SEIZURE; SIDE EFFECT; SKIN INFECTION; SKIN MANIFESTATION; SKIN ULCER; THROMBOCYTOPENIA; TREMOR; TRICHOMONIASIS; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI; URINARY TRACT INFECTION; VAGINITIS; VOMITING; WOUND;

AFRICA; ANIMALS; BENZAMIDES; CHAGAS DISEASE; HUMANS; INSECT VECTORS; LATIN AMERICA; NIFURTIMOX; NITRO COMPOUNDS; NITROIMIDAZOLES; NITROREDUCTASES; PHOSPHORAMIDE MUSTARDS; PRODRUGS; PROTOZOAN PROTEINS; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS, AFRICAN;

EID: 80051701708     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611796575894     Document Type: Article

References (135)

1. Barrett, M. P.; Burchmore, R. J.; Stich, A.; Lazzari, J. O.; Frasch, A. C.; Cazzulo, J. J.; Krishna, S. The trypanosomiases. Lancet, 2003, 362, 1469-1480.
2. Wilkinson, S. R.; Kelly, J. M. Trypanocidal drugs: mechanisms, resistance and new targets. Exp. Rev. Mol. Med., 2009, 11, e31.
3. Barrett, M. P. The rise and fall of sleeping sickness. Lancet, 2006, 367, 1377-1378.
4. Schofield, C. J.; Jannin, J.; Salvatella, R. The future of Chagas disease control. Trends Parasitol., 2006, 22, 583-588.
5. Simarro, P. P.; Jannin, J.; Cattand, P. Eliminating human African trypanosomiasis: where do we stand and what comes next? PLoS Med., 2008, 5, e55.
6. Steverding, D. The history of African trypanosomiasis. Parasit Vectors, 2008, 1, 3.
7. Brun, R.; Blum, J.; Chappuis, F.; Burri, C. Human African trypanosomiasis. Lancet, 2010, 375, 148-159.
8. Bern, C.; Montgomery, S. P.; Katz, L.; Caglioti, S.; Stramer, S. L. Chagas disease and the US blood supply. Curr. Opin. Infect. Dis., 2008, 21, 476-482.
9. Bern, C.; Montgomery, S. P. An estimate of the burden of Chagas disease in the United States. Clin. Infect. Dis., 2009, 49, e52-54.
10. Gascon, J.; Bern, C.; Pinazo, M. J. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop., 2010, 115, 22-27.
11. Rassi, A. Jr.; Rassi, A.; Marin-Neto, J.A. Chagas disease. Lancet, 2010, 375, 1388-1402.
12. Adams, C. P.; Brantner, V. V. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff., (Millwood) 2006, 25, 420-428.
13. Grunberg, E.; Titsworth, E. H. Chemotherapeutic properties of heterocyclic compounds: monocyclic compounds with fivemembered rings. Annu. Rev. Microbiol., 1973, 27, 317-346.
14. Spain, J. C. Biodegradation of nitroaromatic compounds. Annu. Rev. Microbiol., 1995, 49, 523-555.
15. Peres, C. M.; Agathos, S. N. Biodegradation of nitroaromatic pollutants: from pathways to remediation. Biotechnol. Annu. Rev., 2000, 6, 197-220.
16. Rieger, P. G.; Meier, H. M.; Gerle, M.; Vogt, U.; Groth, T.; Knackmuss, H. J. Xenobiotics in the environment: present and future strategies to obviate the problem of biological persistence. J. Biotechnol., 2002, 94, 101-123.
17. Roldan, M. D.; Perez-Reinado, E.; Castillo, F.; Moreno-Vivian, C. Reduction of polynitroaromatic compounds: the bacterial nitroreductases. FEMS Microbiol. Rev., 2008, 32, 474-500.
18. McCalla, D. R. Mutagenicity of nitrofuran derivatives: review. Environ Mutagen, 1983, 5, 745-765.
19. Denny, W. A. Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy). J. Biomed. Biotechnol., 2003, 2003, 48-70.
20. Saulnier Sholler, G. L.; Kalkunte, S.; Greenlaw, C.; McCarten, K.; Forman, E. Antitumor activity of nifurtimox observed in a patient with neuroblastoma. J. Pediatr. Hematol. Oncol., 2006, 28, 693-695.
21. Chen, Y.; Hu, L. Design of anticancer prodrugs for reductive activation. Med. Res. Rev., 2009, 29, 29-64.
22. Stover, C. K.; Warrener, P.; VanDevanter, D. R.; Sherman, D. R.; Arain, T. M.; Langhorne, M. H.; Anderson, S. W.; Towell, J. A.; Yuan, Y.; McMurray, D. N.; Kreiswirth, B. N.; Barry, C. E.; Baker, W. R. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 2000, 405, 962-966.
23. Kashanian, J.; Hakimian, P.; Blute, M. Jr.; Wong, J.; Khanna, H.; Wise, G.; Shabsigh, R. Nitrofurantoin: the return of an old friend in the wake of growing resistance. B4U Int., 2008, 102, 1634-1637.
24. Arya, S. C.; Agarwal, N. Nitrofurantoin: the return of an old friend in the wake of growing resistance. BJU Int., 2009, 103, 994-995.
25. Manjunatha, U.H.; Boshoff, H.; Dowd, C. S.; Zhang, L.; Albert, T. J.; Norton, J. E.; Daniels, L.; Dick, T.; Pang, S. S.; Barry, C. E. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA, 2006, 103, 431-436.
26. Singh, R.; Manjunatha, U.; Boshoff, H. I. M.; Ha, Y. H.; Niyomrattanakit, P.; Ledwidge, R.; Dowd, C. S.; Lee, I. Y.; Kim, P.; Zhang, L.; Kang, S.; Keller, T. H.; Jiricek, J.; Barry, C. E. PA-824 kills nonreplicating mycobacterium tuberculosis by intracellular no release. Science, 2008, 322, 1392-1395
27. Sokolova, A. Y.; Wyllie, S.; Patterson, S.; Oza, S. L.; Read, K. D.; Fairlamb, A. H. Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis. Antimicrob. Agents Chemother., 2010, 54, 2893-2900.
28. Evens, F.; Niemegeers, K.; Packchanian, A. Nitrofurazone therapy of Trypanosoma gambiense sleeping sickness in man. Am. J. Trop. Med. Hyg., 1957, 6, 665-678.
29. Packchanian, A. Chemotherapy of African sleeping sickness. I. Chemotherapy of experimental Trypanosoma gambiense infection in mice (Mus musculus) with nitrofurazone. Am. J. Trop. Med. Hyg., 1955, 4, 705-711.
30. Rodriques Coura, J.; de Castro, S. L. A critical review on Chagas disease chemotherapy. Mem Inst. Oswaldo Cruz, 2002, 97, 3-24.
31. Grunberg, E.; Beskid, G.; Cleeland, R.; DeLorenzo, W. F.; Titsworth, E.; Scholer, H. J.; Richle, R.; Brener, Z. Antiprotozoan and antibacterial activity of 2-nitroimidazole derivatives. Antimicrob. Agents Chemother., (Bethesda) 1967, 7, 513-519.
32. Bock, M.; Gonnert, R.; Haberkorn, A. Studies with Bay 2502 on animals. Bol. Chil. Parasitol., 1969, 24, 13-19.
33. Ferreira, R. C.; Ferreira, L. C. Mutagenicity of nifurtimox and benznidazole in the Salmonella/microsome assay. Braz J. Med. Biol. Res., 1986, 19, 19-25.
34. Alejandre-Duran, E.; Claramunt, R. M.; Sanz, D.; Vilaplana, M. J.; Molina, P.; Pueyo, C. Study on the mutagenicity of nifurtimox and eight derivatives with the L-arabinose resistance test of Salmonella typhimurium. Mutat. Res., 1988, 206, 193-200.
35. Moraga, A. A.; Graf, U. Genotoxicity testing of antiparasitic nitrofurans in the Drosophila wing somatic mutation and recombination test. Mutagenesis, 1989, 4, 105-110.
36. Priotto, G.; Fogg, C.; Balasegaram, M.; Erphas, O.; Louga, A.; Checchi, F.; Ghabri, S.; Piola, P. Three drug combinations for latestage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin. Trials, 2006, 1, e39.
37. Checchi, F.; Piola, P.; Ayikoru, H.; Thomas, F.; Legros, D.; Priotto, G. Nifurtimox plus eflornithine for late-stage sleeping sickness in uganda: A case series. PLoS Negl. Trop. Dis., 2007, 1, e64.
38. Priotto, G.; Kasparian, S.; Ngouama, D.; Ghorashian, S.; Arnold, U.; Ghabri, S.; Karunakara, U. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clin. Infect. Dis., 2007, 45, 1435-1442.
39. Priotto, G.; Kasparian, S.; Mutombo, W.; Ngouama, D.; Ghorashian, S.; Arnold, U.; Ghabri, S.; Baudin, E.; Buard, V.; Kazadi-Kyanza, S.; Ilunga, M.; Mutangala, W.; Pohlig, G.; Schmid, C.; Karunakara, U.; Torreele, E.; Kande, V. Nifurtimoxeflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet, 2009, 374, 56-64.
40. Saulnier Sholler, G. L.; Brard, L.; Straub, J. A.; Dorf, L.; Illeyne, S.; Koto, K.; Kalkunte, S.; Bosenberg, M.; Ashikaga, T.; Nishi, R. Nifurtimox induces apoptosis of neuroblastoma cells in vitro and in vivo. J. Pediatr. Hematol. Oncol., 2009, 31, 187-193.
41. Viotti, R.; Vigliano, C.; Armenti, H.; Segura, E. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am. Heart J., 1994, 127, 151-162.
42. Reyes, P. A.; Vallejo, M. Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Cochrane Database Syst Rev., 2005, CD004102. Available from http://www.cochrane.org/reviews/en/ab004102.html
43. Perez-Molina, J. A.; Perez-Ayala, A.; Moreno, S.; Fernandez-Gonzalez, M. C.; Zamora, J.; Lopez-Velez, R. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a metaanalysis. J. Antimicrob. Chemother., 2009, 64, 1139-1147.
44. Marin-Neto, J. A.; Rassi, A. Jr.; Avezum, A. Jr.; Mattos, A. C.; Rassi, A.; Morillo, C. A.; Sosa-Estani, S.; Yusuf, S. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst. Oswaldo Cruz, 2009, 104 (Suppl 1), 319-324.
45. Peterson, F. J.; Mason, R. P.; Hovsepian, J.; Holtzman, J. L. Oxygen-sensitive and -insensitive nitroreduction by Escherichia coli and rat hepatic microsomes. J. Biol. Chem., 1979, 254, 4009-4014.
46. Nixon, J. E.; Wang, A.; Field, J.; Morrison, H. G.; McArthur, A. G.; Sogin, M. L.; Loftus, B. J.; Samuelson, J. Evidence for lateral transfer of genes encoding ferredoxins, nitroreductases, NADH oxidase, and alcohol dehydrogenase 3 from anaerobic prokaryotes to Giardia lamblia and Entamoeba histolytica. Eukaryot Cell, 2002, 1, 181-190.
47. Muller, J.; Wastling, J.; Sanderson, S.; Muller, N.; Hemphill, A. A novel Giardia lamblia nitroreductase, GlNR1, interacts with nitazoxanide and other thiazolides. Antimicrob. Agents Chemother., 2007, 51, 1979-1986.
48. Wilkinson, S. R.; Taylor, M. C.; Horn, D.; Kelly, J. M.; Cheeseman, I. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc. Natl. Acad. Sci. USA, 2008, 105, 5022-5027.
49. Pal, D.; Banerjee, S.; Cui, J.; Schwartz, A.; Ghosh, S. K.; Samuelson, J. Giardia, Entamoeba, and Trichomonas enzymes activate metronidazole (nitroreductases) and inactivate metronidazole (nitroimidazole reductases). Antimicrob. Agents Chemother., 2009, 53, 458-464.
50. McCalla, D. R.; Reuvers, A.; Kaiser, C. Breakage of bacterial DNA by nitrofuran derivatives. Cancer Res., 1971, 31, 2184-2188.
51. Streeter, A. J.; Hoener, B. A. Evidence for the involvement of a nitrenium ion in the covalent binding of nitrofurazone to DNA. Pharm. Res., 1988, 5, 434-436.
52. Gavin, J. J.; Ebetino, F. F.; Freedman, R.; Waterbury, W. E. The aerobic degradation of 1-(5-nitrofurfurylideneamino)-2-imidazolidinone (NF-246) by Escherichia coli. Arch. Biochem. Biophys., 1966, 113, 399-404.
53. Panicucci, R.; McClelland, R.A. 4,5-dihydro-4,5-dihydroxylimidazoles as products of the reduction of 2- nitroimidazoles, HPLC assay and demonstration of equilibrium transfer of glyoxal to guanine. Can. J. Chem., 1989, 67, 2128-2135.
54. Whitmore, G. F.; Varghese, A. J. The biological properties of reduced nitroheterocyclics and possible underlying biochemical mechanisms. Biochem. Pharmacol., 1986, 35, 97-103.
55. Whitmore, G. F.; Varghese, A. J.; Gulyas, S. Reaction of 2-nitroimidazole metabolites with guanine and possible biological consequences. IARC Sci. Publ., 1986, (70), 185-196.
56. Mason, R. P.; Holtzman, J. L. The mechanism of microsomal and mitochondrial nitroreductase. Electron spin resonance evidence for nitroaromatic free radical intermediates. Biochemistry, 1975, 14, 1626-1632.
57. Docampo, R.; Stoppani, A. O. Generation of superoxide anion and hydrogen peroxide induced by nifurtimox in Trypanosoma cruzi. Arch. Biochem. Biophys., 1979, 197, 317-321.
58. Moreno, S. N.; Mason, R. P.; Muniz, R. P.; Cruz, F. S.; Docampo, R. Generation of free radicals from metronidazole and other nitroimidazoles by Tritrichomonas foetus. J. Biol. Chem., 1983, 258, 4051-4054.
59. Docampo, R.; Mason, R. P.; Mottley, C.; Muniz, R. P. Generation of free radicals induced by nifurtimox in mammalian tissues. J. Biol. Chem., 1981, 256, 10930-10933.
60. Giulivi, C.; Turrens, J. F.; Boveris, A. Chemiluminescence enhancement by trypanocidal drugs and by inhibitors of antioxidant enzymes in Trypanosoma cruzi. Mol. Biochem. Parasitol., 1988, 30, 243-251.
61. Docampo, R. Sensitivity of parasites to free radical damage by antiparasitic drugs. Chem. Biol. Interact, 1990, 73, 1-27.
62. Viode, C.; Bettache, N.; Cenas, N.; Krauth-Siegel, R. L.; Chauviere, G.; Bakalara, N.; Perie, J. Enzymatic reduction studies of nitroheterocycles. Biochem. Pharmacol., 1999, 57, 549-557.
63. Henderson, G. B.; Ulrich, P.; Fairlamb, A. H.; Rosenberg, I.; Pereira, M.; Sela, M.; Cerami, A. Subversive substrates for the enzyme trypanothione disulfide reductase: alternative approach to chemotherapy of Chagas disease. Proc. Natl. Acad. Sci. USA, 1988, 85, 5374-5378.
64. Blumenstiel, K.; Schoneck, R.; Yardley, V.; Croft, S. L.; Krauth-Siegel, R. L. Nitrofuran drugs as common subversive substrates of Trypanosoma cruzi lipoamide dehydrogenase and trypanothione reductase. Biochem. Pharmacol., 1999, 58, 1791-1799.
65. Boveris, A.; Sies, H.; Martino, E. E.; Docampo, R.; Turrens, J. F.; Stoppani, A. O. Deficient metabolic utilization of hydrogen peroxide in Trypanosoma cruzi. Biochem. J., 1980, 188, 643-648.
66. Fairlamb, A. H.; Cerami, A. Metabolism and functions of trypanothione in the Kinetoplastida. Annu. Rev. Microbiol., 1992, 46, 695-729.
67. Flohe, L.; Hecht, H. J.; Steinert, P. Glutathione and trypanothione in parasitic hydroperoxide metabolism. Free Radic. Biol. Med., 1999, 27, 966-984.
68. Wilkinson, S. R.; Obado, S. O.; Mauricio, I. L.; Kelly, J. M. Trypanosoma cruzi expresses a plant-like ascorbate-dependent hemoperoxidase localized to the endoplasmic reticulum. Proc. Natl. Acad. Sci. USA, 2002, 99, 13453-13458.
69. Wilkinson, S. R.; Kelly, J. M. The role of glutathione peroxidases in trypanosomatids. Biol. Chem., 2003, 384, 517-525.
70. Irigoin, F.; Cibils, L.; Comini, M. A.; Wilkinson, S. R.; Flohe, L.; Radi, R. Insights into the redox biology of Trypanosoma cruzi: Trypanothione metabolism and oxidant detoxification. Free Radic. Biol. Med., 2008, 45, 733-742.
71. Moreno, S. N.; Docampo, R.; Mason, R. P.; Leon, W.; Stoppani, A. O. Different behaviors of benznidazole as free radical generator with mammalian and Trypanosoma cruzi microsomal preparations. Arch. Biochem. Biophys., 1982, 218, 585-591.
72. Prathalingham, S. R.; Wilkinson, S. R.; Horn, D.; Kelly, J. M. Deletion of the Trypanosoma brucei superoxide dismutase gene sodb1 increases sensitivity to nifurtimox and benznidazole. Antimicrob. Agents Chemother., 2007, 51, 755-758.
73. Kelly, J. M.; Taylor, M. C.; Smith, K.; Hunter, K. J.; Fairlamb, A. H. Phenotype of recombinant Leishmania donovani and Trypanosoma cruzi which over-express trypanothione reductase. Sensitivity towards agents that are thought to induce oxidative stress. Eur. J. Biochem., 1993, 218, 29-37.
74. Wilkinson, S. R.; Temperton, N. J.; Mondragon, A.; Kelly, J. M. Distinct mitochondrial and cytosolic enzymes mediate trypanothione-dependent peroxide metabolism in Trypanosoma cruzi. J. Biol. Chem., 2000, 275, 8220-8225.
75. Wilkinson, S. R.; Meyer, D. J.; Taylor, M. C.; Bromley, E. V.; Miles, M. A.; Kelly, J. M. The Trypanosoma cruzi enzyme TcGPXI is a glycosomal peroxidase and can be linked to trypanothione reduction by glutathione or tryparedoxin. J. Biol. Chem., 2002, 277, 17062-17071.
76. Wilkinson, S. R.; Horn, D.; Prathalingam, S. R.; Kelly, J. M. RNA interference identifies two hydroperoxide metabolizing enzymes that are essential to the bloodstream form of the african trypanosome. J. Biol. Chem., 2003, 278, 31640-31646.
77. Wilkinson, S. R.; Prathalingam, S. R.; Taylor, M. C.; Ahmed, A.; Horn, D.; Kelly, J. M. Functional characterisation of the iron superoxide dismutase gene repertoire in Trypanosoma brucei. Free Radic. Biol. Med., 2006, 40, 198-209.
78. McCalla, D. R.; Kaiser, C.; Green, M. H. Genetics of nitrofurazone resistance in Escherichia coli. J. Bacteriol., 1978, 133, 10-16.
79. Whiteway, J.; Koziarz, P.; Veall, J.; Sandhu, N.; Kumar, P.; Hoecher, B.; Lambert, I. B. Oxygen-insensitive nitroreductases: analysis of the roles of nfsA and nfsB in development of resistance to 5-nitrofuran derivatives in Escherichia coli. J. Bacteriol., 1998, 180, 5529-5539.
80. Kubata, B. K.; Kabututu, Z.; Nozaki, T.; Munday, C. J.; Fukuzumi, S.; Ohkubo, K.; Lazarus, M.; Maruyama, T.; Martin, S. K.; Duszenko, M.; Urade, Y. A key role for old yellow enzyme in the metabolism of drugs by Trypanosoma cruzi. J. Exp. Med., 2002, 196, 1241-1251.
81. De Carneri, I. Antiprotozoan activity of nitroimidazoles. Arzneimittelforschung, 1969, 19, 382-386.
82. Ross, W. J.; Jamieson, W. B.; McCowen, M. C. Antiparasitic nitroimidazoles.1. Some 2-styryl-5-nitroimidazoles. J. Med. Chem., 1972, 15, 1035-1040.
83. Ross, W. J.; Jamieson, W. B.; McCowen, M. C. Antiparasitic nitroimidazoles. 3. Synthesis of 2-(4-carboxystyryl)-5-nitro-1-vinylimidazole and related compounds. J. Med. Chem., 1973, 16, 347-352.
84. Ross, W. J.; Todd, A. Antiparasitic nitroimidazoles. 7. Some 4- and 5-styrylnitroimidazoles. J. Med. Chem., 1973, 16, 863-865.
85. Ross, W. J.; Jamieson, W. B. Antiparasitic nitroimidazoles. 9. Synthesis of some 2-(4-dialkylaminomethylstyryl)-and 2-(4-amidinostyryl)5-nitro-1-vinylimidazoles. J. Med. Chem., 1975, 18, 430-432.
86. Ross, W. J.; Jamieson, W. B. Antiparasitic nitroimidazoles. 8. Derivatives of 2-(4-formylstyryl)-5-nitro-1-vinylimidazole. J. Med. Chem., 1975, 18, 158-161.
87. Winkelmann, E.; Raether, W.; Gebert, U.; Sinharay, A. Chemotherapeutically active nitro compounds. 4. 5-Nitroimidazoles (Part I). Arzneimittelforschung, 1977, 27, 2251-2263.
88. Winkelmann, E.; Raether, W.; Gebert, U. Chemotherapeutically active nitro-derivatives. 4. 5-Nitroimidazoles (Part IV). Arzneimittelforschung, 1978, 28, 1682-1684.
89. Winkelmann, E.; Raether, W.; Sinharay, A. Chemotherapeutically active nitro compounds. 4.5-Nitroimidazoles (Part II). Arzneimittelforschung, 1978, 28, 351-366.
90. Winkelmann, E.; Raether, W. Chemotherapeutically acitve nitro compounds. 4. 5-Nitroimidazoles (Part III). Arzneimittelforschung, 1978, 28, 739-749.
91. Raether, W.; Seidenath, H. The activity of fexinidazole (HOE 239) against experimental infections with Trypanosoma cruzi, trichomonads and Entamoeba histolytica. Ann. Trop. Med. Parasitol., 1983, 77, 13-26.
92. Cerecetto, H.; Di Maio, R.; Ibarruri, G.; Seoane, G.; Denicola, A.; Peluffo, G.; Quijano, C.; Paulino, M. Synthesis and antitrypanosomal activity of novel 5-nitro-2-furaldehyde and 5-nitrothiophene-2-carboxaldehyde semicarbazone derivatives. Farmaco, 1998, 53, 89-94.
93. Cerecetto, H.; Di Maio, R.; Gonzalez, M.; Risso, M.; Sagrera, G.; Seoane, G.; Denicola, A.; Peluffo, G.; Quijano, C.; Stoppani, A. O.; Paulino, M.; Olea-Azar, C.; Basombrio, M. A. Synthesis and antitrypanosomal evaluation of E-isomers of 5-nitro-2-furaldehyde and 5-nitrothiophene-2-carboxaldehyde semicarbazone derivatives. structure-activity relationships. Eur. J. Med. Chem., 2000, 35, 343-350.
94. Aguirre, G.; Cabrera, E.; Cerecetto, H.; Di Maio, R.; Gonzalez, M.; Seoane, G.; Duffaut, A.; Denicola, A.; Gil, M. J.; Martinez-Merino, V. Design, synthesis and biological evaluation of new potent 5-nitrofuryl derivatives as anti-Trypanosoma cruzi agents. Studies of trypanothione binding site of trypanothione reductase as target for rational design. Eur. J. Med. Chem., 2004, 39, 421-431.
95. Stewart, M. L.; Bueno, G. J.; Baliani, A.; Klenke, B.; Brun, R.; Brock, J. M.; Gilbert, I. H.; Barrett, M. P. Trypanocidal activity of melamine-based nitroheterocycles. Antimicrob. Agents Chemother., 2004, 48, 1733-1738.
96. Baliani, A.; Bueno, G. J.; Stewart, M. L.; Yardley, V.; Brun, R.; Barrett, M. P.; Gilbert, I. H. Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites. J. Med. Chem., 2005, 48, 5570-5579.
97. Aguirre, G.; Boiani, M.; Cabrera, E.; Cerecetto, H.; Di Maio, R.; Gonzalez, M.; Denicola, A.; Sant'anna, C. M.; Barreiro, E. J. New potent 5-nitrofuryl derivatives as inhibitors of Trypanosoma cruzi growth. 3D-QSAR (CoMFA) studies. Eur. J. Med. Chem., 2006, 41, 457-466.
98. Gerpe, A.; Odreman-Nunez, I.; Draper, P.; Boiani, L.; Urbina, J. A.; Gonzalez, M.; Cerecetto, H. Heteroallyl-containing 5-nitrofuranes as new anti-Trypanosoma cruzi agents with a dual mechanism of action. Bioorg. Med. Chem., 2008, 16, 569-577.
99. Gerpe, A.; Alvarez, G.; Benitez, D.; Boiani, L.; Quiroga, M.; Hernandez, P.; Sortino, M.; Zacchino, S.; Gonzalez, M.; Cerecetto, H. 5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene. Bioorg. Med. Chem., 2009, 17, 7500-7509.
100. Baliani, A.; Peal, V.; Gros, L.; Brun, R.; Kaiser, M.; Barrett, M. P.; Gilbert, I. H. Novel functionalized melamine-based nitroheterocycles: synthesis and activity against trypanosomatid parasites. Org. Biomol. Chem., 2009, 7, 1154-1166.
101. Hwang, J. Y.; Smithson, D.; Connelly, M.; Maier, J.; Zhu, F.; Guy, K. R. Discovery of halo-nitrobenzamides with potential application against human African trypanosomiasis. Bioorg. Med. Chem. Lett., 2010, 20, 149-152.
102. Filardi, L. S.; Brener, Z. A nitroimidazole-thiadiazole derivative with curative action in experimental Trypanosoma cruzi infections. Ann. Trop. Med. Parasitol., 1982, 76, 293-297.
103. Bouteille, B.; Marie-Daragon, A.; Chauviere, G.; de Albuquerque, C.; Enanga, B.; Darde, M. L.; Vallat, J. M.; Perie, J.; Dumas, M. Effect of megazol on Trypanosoma brucei brucei acute and subacute infections in Swiss mice. Acta Trop., 1995, 60, 73-80.
104. Barrett, M. P.; Fairlamb, A. H.; Rousseau, B.; Chauviere, G.; Perie, J. Uptake of the nitroimidazole drug megazol by African trypanosomes. Biochem. Pharmacol., 2000, 59, 615-620.
105. Poli, P.; Aline de Mello, M.; Buschini, A.; Mortara, R. A.; Northfleet de Albuquerque, C.; da Silva, S.; Rossi, C.; Zucchi, T. M. Cytotoxic and genotoxic effects of megazol, an anti-Chagas' disease drug, assessed by different short-term tests. Biochem. Pharmacol., 2002, 64, 1617-1627.
106. Enanga, B.; Ariyanayagam, M. R.; Stewart, M. L.; Barrett, M. P. Activity of megazol, a trypanocidal nitroimidazole, is associated with DNA damage. Antimicrob. Agents, Chemother., 2003, 47, 3368-3370.
107. Nesslany, F.; Brugier, S.; Mouries, M. A.; Le Curieux, F.; Marzin, D. In vitro and in vivo chromosomal aberrations induced by megazol. Mutat. Res., 2004, 560, 147-158.
108. Chauviere, G.; Bouteille, B.; Enanga, B.; de Albuquerque, C.; Croft, S. L.; Dumas, M.; Perie, J. Synthesis and biological activity of nitro heterocycles analogous to megazol, a trypanocidal lead. J. Med. Chem., 2003, 46, 427-440.
109. Carvalho, S. A.; da Silva, E. F.; Santa-Rita, R. M.; de Castro, S. L.; Fraga, C. A. Synthesis and antitrypanosomal profile of new functionalized 1,3,4-thiadiazole-2-arylhydrazone derivatives, designed as non-mutagenic megazol analogues. Bioorg. Med. Chem. Lett., 2004, 14, 5967-5970.
110. Carvalho, A. S.; Menna-Barreto, R. F.; Romeiro, N. C.; de Castro, S. L.; Boechat, N. Design, synthesis and activity against Trypanosoma cruzi of azaheterocyclic analogs of megazol. Med. Chem., 2007, 3, 460-465.
111. Carvalho, S. A.; Lopes, F. A.; Salomao, K.; Romeiro, N. C.; Wardell, S. M.; de Castro, S. L.; da Silva, E. F.; Fraga, C. A. Studies toward the structural optimization of new brazilizone-related trypanocidal 1,3,4-thiadiazole-2-arylhydrazone derivatives. Bioorg. Med. Chem., 2008, 16, 413-421.
112. Salomao, K.; de Souza, E. M.; Carvalho, S. A.; da Silva, E. F.; Fraga, C. A.; Barbosa, H. S.; de Castro, S. L. In vitro and in vivo activity of 1,3,4-thiadiazole-2-arylhydrazone derivatives of megazol on Trypanosoma cruzi. Antimicrob. Agents Chemother., 2010, 54, 2023-2031.
113. Hu, L.; Yu, C.; Jiang, Y.; Han, J.; Li, Z.; Browne, P.; Race, P. R.; Knox, R. J.; Searle, P. F.; Hyde, E. I. Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy. J. Med. Chem., 2003, 46, 4818-4821.
114. Jiang, Y.; Han, J.; Yu, C.; Vass, S. O.; Searle, P. F.; Browne, P.; Knox, R. J.; Hu, L. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation. J. Med. Chem., 2006, 49, 4333-4343.
115. Hall, B. S.; Wu, X.; Hu, L.; Wilkinson, S. R. Exploiting the drugactivating properties of a novel trypanosomal nitroreductase. Antimicrob. Agents Chemother., 2010, 54, 1193-1199.
116. Chung-Faye, G.; Palmer, D.; Anderson, D.; Clark, J.; Downes, M.; Baddeley, J.; Hussain, S.; Murray, P. I.; Searle, P.; Seymour, L.; Harris, P. A.; Ferry, D.; Kerr, D. J. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin. Cancer Res., 2001, 7, 2662-2668.
117. Patel, P.; Young, J. G.; Mautner, V.; Ashdown, D.; Bonney, S.; Pineda, R. G.; Collins, S. I.; Searle, P. F.; Hull, D.; Peers, E.; Chester, J.; Wallace, D. M.; Doherty, A.; Leung, H.; Young, L. S.; James, N. D. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]. Mol. Ther., 2009, 17, 1292-1299.
118. Knox, R. J.; Friedlos, F.; Sherwood, R. F.; Melton, R. G.; Anlezark, G. M. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase. Biochem. Pharmacol., 1992, 44, 2297-2301.
119. Knox, R. J.; Friedlos, F.; Biggs, P. J.; Flitter, W. D.; Gaskell, M.; Goddard, P.; Davies, L.; Jarman, M. Identification, synthesis and properties of 5-(aziridin-1-yl)-2-nitro-4-nitrosobenzamide, a novel DNA crosslinking agent derived from CB1954. Biochem. Pharmacol., 1993, 46, 797-803.
120. Helsby, N. A.; Wheeler, S. J.; Pruijn, F. B.; Palmer, B. D.; Yang, S.; Denny, W. A.; Wilson, W. R. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation. Chem. Res. Toxicol., 2003, 16, 469-478.
121. Helsby, N. A.; Ferry, D. M.; Patterson, A. V.; Pullen, S. M.; Wilson, W. R. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT. Br. J. Cancer, 2004, 90, 1084-1092.
122. Tang, M. H.; Helsby, N. A.; Wilson, W. R.; Tingle, M. D. Aerobic 2- and 4-nitroreduction of CB 1954 by human liver. Toxicology, 2005, 216, 129-139.
123. Barrett, S. V.; Barrett, M. P. Anti-sleeping sickness drugs and cancer chemotherapy. Parasitol. Today, 2000, 16, 7-9.
124. Legros, D.; Ollivier, G.; Gastellu-Etchegorry, M.; Paquet, C.; Burri, C.; Jannin, J.; Buscher, P. Treatment of human African trypanosomiasis--present situation and needs for research and development. Lancet Infect. Dis., 2002, 2, 437-440.
125. Docampo, R.; Moreno, S. N. Current chemotherapy of human African trypanosomiasis. Parasitol. Res., 2003, 90 (Supp 1), S10-S13.
126. Nok, A. J. Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis. Parasitol. Res., 2003, 90, 71-79.
127. Filardi, L. S.; Brener, Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans. R Soc. Trop. Med. Hyg., 1987, 81, 755-759.
128. Castro, J. A.; Diaz de Toranzo, E. G. Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas' disease). Biomed. Environ. Sci., 1988, 1, 19-33.
129. Ferreira, R. C.; Schwarz, U.; Ferreira, L. C. Activation of anti-Trypanosoma cruzi drugs to genotoxic metabolites promoted by mammalian microsomal enzymes. Mutat. Res., 1988, 204, 577-583.
130. Gorla, N. B.; Ledesma, O. S.; Barbieri, G. P.; Larripa, I. B. Thirteenfold increase of chromosomal aberrations non-randomly distributed in chagasic children treated with nifurtimox. Mutat. Res., 1989, 224, 263-267.
131. Teixeira, A. R.; Cordoba, J. C.; Souto Maior, I.; Solorzano, E. Chagas' disease: lymphoma growth in rabbits treated with Benznidazole. Am. J. Trop. Med Hyg., 1990, 43, 146-158.
132. Teixeira, A. R.; Calixto, M. A.; Teixeira, M. L. Chagas' disease: carcinogenic activity of the antitrypanosomal nitroarenes in mice. Mutat. Res., 1994, 305, 189-196.
133. Murta, S. M.; Gazzinelli, R. T.; Brener, Z.; Romanha, A. J. Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. Mol. Biochem. Parasitol., 1998, 93, 203-214.
134. Iatropoulos, M. J.; Wang, C. X.; von Keutz, E.; Williams, G. M. Assessment of chronic toxicity and carcinogenicity in an accelerated cancer bioassay in rats of Nifurtimox, an antitrypanosomiasis drug. Exp. Toxicol. Pathol., 2006, 57, 397-404.
135. Castro, J. A.; de Mecca, M. M.; Bartel, L. C. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum. Exp. Toxicol., 2006, 25, 471-479.